1Pols H, Eastell R, Delmas P. Early onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis:4-year results from the MORE trial [J] . Bone, 1998, 28(5):S85.
2Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial [J] . J Clin Endocrinol Metab,2002,87(8):3609.
3Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial [J] . JAMA, 1999, 282:637.
4Barrett-Connor E, Grady D, Sashegui A, et al. Raloxifene and cardiovascular events in osteoporotic pos menopansal women [J] . JAMA, 2002,287:847.
5Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis [ J] . Arch Iht Med, 2002,162(10):1140.
6Michael Maricic, Oscar Gluck. Review of raloxifene and its clinical applications in osteoporosis [ J] . Expert Opin Pharmacother, 2002, 3(6):767.
7Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects on bone mineral density, serum cholesterol concentration and ulerine endometrium in postmenopausal women[J]. N Engl J Med, 1977, 337:1641.
8Cummings S, Eckert S, Krueper K, et al. The effect of raloxifene or risk of breast cancer in postmenopausal women. Results from the MORE randomized trial [ J ] .JAMA, 1999, 281:2189.
9Cauley JA, Norton L, Lippman ME, et al. Continued breast risk reduction in postmenopausal women treatedwith raloxifene: 4-year results from the MORE trial[J]. Br Cancer Res Treat, 2001, 65:125.
10Walsh BW, Paul S, Wild RA, et al. Effects ofraloxifene on serum lipids and coagulation factors in healthy post menopausal women [J] . JAMA, 1998, 279:1445.
